Illumina, Inc.: Takeaways from dinner with ILMN at the 2026 BofA healthcare conference

Research evidence excerpt

Illumina, Inc.: Takeaways from dinner with ILMN at the 2026 BofA healthcare conference

ILMN Investment Opinion C-3-9

pointed to ongoing questions around workflow complexity, throughput, hands-on time, 52-Week Range 77.50 USD - 155.53 USD

consumable economics, reuse requirements and real-world scalability. The company Mrkt Val (mn) / Shares Out 23,055 USD / 159.0

emphasized it has not yet seen evidence of meaningful market disruption, customer (mn)

pauses or slower NovaSeq X adoption trends following Roche’s launch. Commentary also Free Float 97.1%

suggested that early customer interest appears concentrated among innovation-oriented Average Daily Value (mn) 222.12 USD

adopters, with broader adoption likely dependent on additional real-world validation and BofA Ticker / Exchange ILMN / NAS

workflow experience over time. The company reiterated confidence in its installed base, Bloomberg / Reuters ILMN US / ILMN.OQ

customer relationships, and ongoing innovation roadmap, while acknowledging ROE (2026E) 27.1%

competition could contribute to incremental pricing pressure over time. Net Dbt to Eqty (Dec-2025A) 13.1%

NovaseqX placements and backlog trends remain elevated

Stronger-than-expected NovaSeq X placement activity remained a key area of focus,

including ~83 instrument placements in 1Q26 and continued strength among larger HSD; high-single digits

clinical customers. ILMN noted backlog trends remained elevated, with consumables

representing the majority of the backlog activity, while also acknowledging demand NT: Near term

trends have at times exceeded internal manufacturing expectations and capacity

planning assumptions. Discussion also touched on the pace of customer ramp activity

following placements, with typical clinical ramps described as occurring over roughly 2-3